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Abstract 
Objective: This study sought to investigate the effect of Spirulina on cardiometabolic
risk factors, oxidative stress biomarkers, glycemic profile, and liver enzymes in nonal-
coholic fatty liver disease (NAFLD) patients. 
Methods: This randomized, double-blind clinical trial was performed on 46 NAFLD 
patients. Subjects were allocated to consume either Spirulina sauce or placebo, each
20 g/day for 8 weeks. Fatty liver grade, liver enzymes, anthropometric parameters, 
blood pressure, and serum lipids, glucose, insulin, malondialdehyde, and antioxidant 
capacity were assessed pre- and postintervention. 
Results: Fatty liver grade was significantly different between the two groups. A sig-
nificant change for ALT (alanine aminotransferase) and AST (aspartate aminotrans-
ferase) was seen between the two groups (p = .03 and .02, respectively), while ALP 
(alkaline phosphatase) serum levels were not significantly different within or be-
tween groups. Pertaining to glycemic profile, all variables, except HOMA-IR, were 
not significantly different within or between groups. Finally, statistically significant 
changes were seen in both MDA (malondialdehyde) and TAC (total antioxidant capac-
ity) among the groups (p = .04 and <.001, respectively). 
Conclusions: Spirulina may improve fatty liver grade by modifying liver enzymes, 
oxidative stress, and some lipid profiles; however, there was effect of Spirulina on 
anthropometric characteristics and blood pressure. 
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1  | INTRODUC TION  
Nonalcoholic fatty liver disease (NAFLD) is a global public health 
concern, with a high prevalence, impacting around 11%–16% of the 
population (Williams et al., 2011). NAFLD prevalence in Asia is re-
ported to be 6%–25% (Fan, 2007) and ~2.9% in Iranian adults (Rogha 
et al., 2011). NAFLD is characterized by an increase in fat in the liver 
cells (Bellentani et al., 2000; Ma et al., 2020; Neuschwander-Tetri & 
Caldwell, 2003); although it is normal for the liver to have some fat, 
when it exceeds 5% of liver weight, further complications are often 
present (Raziel et al., 2015). Indeed, the clinical importance of this 
disease is attributable to the liver cell apoptosis and the destruc-
tion of liver tissue, and if not diagnosed early and properly treated, 
irreversible cirrhosis of the liver can occur. Concomitant to NAFLD, 
increased blood pressure and body fat, obesity, diabetes, and in-
sulin resistance, components of metabolic syndrome, are routinely 
observed (Aller et al., 2015; Ludwig et al., 1980; Raziel et al., 2015; 
Wang et al., 2019). 
Contemporary treatment for NAFLD generally includes life-
style modifications, particularly diet and physical activity (Rezaei
et al., 2019). In this regard, functional foods have been shown to be 
effective in helping control metabolic dysfunction. For instance, it 
has been asserted that Spirulina intake can modify cholesterol, ex-
pand the antioxidant capacity, and decrease insulin resistance and 
glucose uptake (Moura et al., 2011). Spirulina is a multicellular, fi-
brous green algae found naturally in alkaline lakes. Furthermore, it 
is cultivated in a controlled environment for human consumption 
and is considered a healthy food without side effects by the United 
Nations Development Program (Pham et al., 2019). Spirulina is used 
as a dietary compound, due to large quantities of antioxidants 
(Hossain et al., 2016) such as creatine, phycocyanin (containing the
triple-pyrrole chromophore, identified as phycocyanobilin, which is
covalently attached to apoprotein), minerals K, Na, Ca, Mg, Fe, and 
Zn, vitamins (tocopherols), eight crucial amino acids, unsaturated 
fatty acids, particularly linolenic acid, omega-3 and omega-6 fatty
acids, and phenolic compounds (Ferreira-Hermosillo et al., 2010;
Moura et al., 2011; Neyrinck et al., 2017; Vázquez-Velasco 
et al., 2017). Moreover, it purportedly possesses a good source 
of protein (containing 65–70% dry weight) (Moura et al., 2011; 
Neyrinck et al., 2017). Due to its anti-inflammatory effects, Spirulina
is consumed as a dietary supplement in many countries (Neyrinck 
et al., 2017). Previous studies have shown positive influences of 
Spirulina on NAFLD, oxidative stress, hyperglycemia, hypocholes-
terolemia, malnutrition, anemia, allergic rhinitis, cancer, substance
toxicity reduction, and arterial hypertension (Fujimoto et al., 2012; 
Moura et al., 2011; Neyrinck et al., 2017). Indeed, Spirulina protects 
against liver toxicity in murine models by enhancing cellular antiox-
idant enzymes, such as superoxide dismutase, glutathione peroxi-
dase, and catalase (Premkumar et al., 2004). Moreover, it has been 
confirmed in animal and human studies that protection against in-
flammatory diseases, including colitis and arthritis, may be conferred 
(Pham et al., 2019). 
Therefore, due to the prevalence of NAFLD, and the relation-
ship between fatty liver disease and high blood pressure, obesity,
diabetes, and insulin resistance, concomitant to the limited num-
ber of human-based studies in this field, we sought to investigate
the effect of Spirulina on cardiometabolic risk factors, oxidative
stress biomarkers, glycemic profile, and liver enzymes in NAFLD
patients. 
2  | METHODS AND MATERIAL S  
2.1 | Study design and characteristics of patients 
This present study was conducted as a double-blinded randomized 
controlled trial that conformed to the Declaration of Helsinki and 
Good Clinical Practice Guidelines. Our study protocol was re-
viewed and accepted by the ethics committee of Baqiyatallah 
University of Medical Sciences in Iran (approval number: IR.BMSU. 
REC. 1398.312) and enrolled in the Iranian Registry of Clinical Trials 
(IRCT20200304046692N1 registered on 2020-03-11). Eligible pa-
tients were those with NAFLD who were referred to clinical health 
care. 
Inclusion criteria were as follows: NAFLD diagnosis by the
physician (using ultrasound) and age ranges from 18 to 70 years.
Individuals were not included if they were diagnosed with other
diseases, such as cardiovascular disease, liver disease (cirrhosis,
alcoholic liver disease, viral hepatitis, autoimmune hepatitis, bili-
ary obstruction, primary biliary cirrhosis, and hepatic injury), can-
cer, renal failure, or celiac. In addition, pregnant and/or lactating
women, taking drugs that cause fatty liver (methotrexate, tamox-
ifen, valproate, etc.), taking lipid-lowering drugs, malnutrition that
required nutritional support, following special diets such as vege-
tarian or raw vegetarian, and alcohol consumption were further ex-
clusory factors. Finally, participants were excluded from the study
if they did not follow the recommended treatment, were unwilling
to continue the study, and had any acute diseases or infections
during the study and if hospitalization occurred for period more
than 5 days. 
2.2 | Sample size 
The sample size was estimated to be 19 participants in each group, 
with a power (1−β) of 80% and α = 0.05, in line with a previous study
(Mazokopakis et al., 2014). We estimated a 20% attrition rate, and 
thus, 23 patients were recruited in each group. 
2.3 | Randomization 
We assigned 46 patients randomly in a 1:1 ratio, to the Spirulina
sauce and placebo groups, respectively. To assign participants, 
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blocked randomization with a fixed block size of 4 was used and 
done by a researcher who had no clinical involvement in our study. 
2.4 | Blinding 
To blind patients to the samples, the sauce sachets in both groups 
were identical in appearance, taste, and color. The sauce sachets 
were coded differently in each group to blind the investigator. 
2.5 | Intervention 
Participants in the Spirulina sauce group consumed one sachet
(20 mg) of sauce containing 2 gr Spirulina per day for 8 consec-
utive weeks and similarly in the placebo group received one sa-
chet (20 mg) of placebo per day. The sauce was produced in the
Namakin factory in Shiraz, Iran. To produce the sauce, raw materi-
als including oil, lemon juice, vinegar, salt, gum, spices, and water
were used. 10% of Spirulina was added to the formula of sauces in
the Spirulina sauce group, and to normalize the sensory proper-
ties, including the color of the sauce, natural dark green chloro-
phyll with international code E-141 was used in the products of
the placebo. The sauces were similar in terms of fat, carbohydrate,
salt, flavorings, and packaging for the Spirulina sauce and placebo
groups. The chemical composition and caloric content of the sauce
are shown in Table 1. 
2.6 | Outcomes and measurement 
Primary outcomes of this study were changes in the severity of fatty 
liver (grades 1–3), and secondary outcomes included any changes in
anthropometric indices, SBP (systolic blood pressure) and DBP (di-
astolic blood pressure), lipid profile, HOMA-IR, MDA, TAC, athero-
genic index of plasma (AIP), and liver enzymes. 
The demographic questionnaires, through face-to-face anamne-
sis interview, were completed by the main investigator. 12-hr fasting 
blood samples were drawn by certified clinical staff, before and after 
8 weeks. Blood samples were centrifuged, and serums were kept at 
−7℃ in the freezer until final measurements for lipid profile, FBS, 
fasting plasma insulin, MDA, TAC, AIP, and liver enzymes. Height 
was measured using a wall-fixed tape to the nearest 0.1 cm. Body 
weight was measured to the nearest 0.1 kg using a scale, while par-
ticipants were in light clothes. Standard methods were considered 
TA B L E  1   The chemical composition and caloric content of the sauce 
to measure waist circumference by a nonstretchable measured tape. 
BMI (body mass index) was computed as weight (kg)/height (m2). 
Blood pressure was measured twice with an interval of at least 5 min, 
using a mercury barometer (ALPK2), and the mean of the two mea-
surements was considered as the subject's blood pressure. Plasma 
glucose levels, lipid profile, and liver enzymes were evaluated using 
an enzymatic colorimetric (GOD-PAP) method (Pars Azmoon Inc.). 
Serum MDA and TAC amounts were assessed by enzyme-linked im-
munosorbent assay (ELISA) (Diaclone). 
We measured insulin sensitivity with the quantitative insulin
sensitivity check index (QUICKI): QUICKI: 1/(log (fasting insulin mU/ 
ml) × log (fasting glucose mg/dl)). 
HOMA-IR: Fasting plasma insulin (mu/ml)_fasting plasma glucose
(mmol/l)/22.5. 
AIP was calculated by log TG/HDL. 
2.7 | Liver ultrasound 
Liver ultrasound was used for fatty liver measurement. A single
expert radiologist was conducted ultrasound measurement. The
grade of echogenicity, the embodiment of the diaphragm, borders 
of the liver vasculature, and incarnation of the posterior portion of 
the right hepatic lobe were used to assess fatty liver's grade (from 
grades 1 to 3). 
2.8 | Statistical methods 
SPSS statistical software (Version 22; IBM) was used for all
data analyses. The normality of the data was evaluated by the
Kolmogorov–Smirnov test. We used a paired t test for the data
with normal distribution and Wilcoxon signed-rank test for non-
normally distributed data to evaluate variations within both groups.
One-way analysis of covariance (ANCOVA) was used for variations
between groups, while a Kruskal–Wallis test was used for the data
with non-normal distribution. Statistical significance was accepted,
a priori, at p < .05. 
3  | RESULTS  
70 patients were assessed and finally, 46 participants completed 
the study. During the study, 7 participants were lost to attrition (the 
Spirulina sauce group = 3 and the placebo group = 4) because of 
Energy 
(kcal/20 gr 
Samples Carbohydrate (%) Protein (%) Fat (%) Fiber (%) Moisture (%) Total ash (%) sauce) 
Spirulina sauce 9.73 7.96 15 7.32 65.65 1.66 32.29 
Placebo 9.47 0.81 15 7.06 73.54 1.18 29.57 
MAZLOOMI et AL.4  |  
F I G U R E  1   Flowchart of the trial 
the following reasons: reluctance to continue, hospitalization, and 
no adherence (Figure 1). Thus, 20 and 19 participants were analyzed 
in the Spirulina sauce and placebo groups, respectively. 
3.1 | Baseline characteristics 
The baseline characteristics of the participants are illustrated in 
Table 2. There was no statistically significant difference between 
the two groups at baseline, except for MDA. 
3.2 | Fatty liver grade and liver enzymes 
Changes in study outcomes are shown in Table 3. In comparison with 
the baseline, fatty liver grade decreased significantly in the Spirulina 
sauce group, concomitant to a nonsignificant increase in the placebo 
group. Between groups, there was a significant difference (p = .007). 
Results indicated that serum concentration of ALT and AST was 
significantly reduced in the Spirulina sauce group, while in the pla-
cebo group, the reduction was not significant. After 8 weeks' in-
tervention, significant changes between the two groups were seen 
| 5 MAZLOOMI et AL.        
  
  





   
 
 




    
      
    
 
    
    
    
    
    
    
    
    
    
     
     
    
     
     
     
    
    






TA B L E  2   Baseline characteristics of 
Spirulina sauce group p‐the participantsa,b 
Variables Placebo group (n = 23) (n = 23) value 
Age, years 35.78 ± 11.14 38.87 ± 14.61 .42 
Males, n (%) 13 (56.5) 9 (39.1) .23 
NAFLD duration, years 3.13 ± 1.57 3.56 ± 1.59 .35 
Weight, kg 72.59 ± 11.87 69.34 ± 10.09 .32 
BMI, kg/m2 25.41 ± 3.45 24.67 ± 2.75 .42 
Waist circumference, cm 95.21 ± 7.10 93.78 ± 6.29 .47 
ALT U/L 37.47 ± 4.37 38.86 ± 4.09 .27 
AST, U/L 21.78 ± 2.66 23.13 ± 2.71 .09 
ALP, U/L 40.52 ± 5.15 43.17 ± 5.73 .10 
Fatty liver grade 1.82 ± 0.65 1.78 ± 0.59 .81 
Fasting blood sugar, mg/dl 87.70 ± 8.63 91.43 ± 7.71 .13 
Insulin, μU/ml 7.36 ± 2.95 8.30 ± 3.27 .31 
Triglycerides, mg/dl 152.83 ± 21.12 165.30 ± 41.20 .20 
Total cholesterol, mg/dl 185.96 ± 39.90 202.48 ± 45 .19 
LDL-C, mg/dl 117.70 ± 40.62 126.96 ± 45.18 .46 
HDL-C, mg/dl 37.61 ± 11.27 42.43 ± 8.28 .10 
MDA, μmol/L 3.69 ± 0.51 4.04 ± 0.44 .01 
TAC, mmol/L 0.50 ± 0.35 0.64 ± 0.26 .12 
SBP, mmHg 127.91 ± 9.79 130.04 ± 7.05 .40 
DBP, mmHg 91.65 ± 5.62 87.60 ± 8.02 .05 
Abbreviations: ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate 
aminotransferase; DBP, diastolic blood pressure; HDL, high-density lipoprotein; LDL, low-density 
lipoprotein; MDA, malondialdehyde; SBP, systolic blood pressure; TAC, total antioxidant capacity. 
The bold value shows a significant difference between the two groups. 
aData are either means ± SD or n (%). 
bQualitative variables were examined with chi-square test; quantitative variables were tested with 
independent t test. 
for both of ALT and AST (p = .03 and .02, respectively). However, 
changes in ALP serum levels were not significant within or between 
groups. 
3.3 | Lipid profiles 
In the Spirulina sauce group, TG serum levels decreased and HDL-C 
serum levels increased significantly, in comparison with the baseline. 
In addition, the changes between the two groups were significant 
for TG (p = .02), and marginally insignificant for HDL-C (p = .07).
Changes in LDL-C and total cholesterol serum levels did not differ 
within or between groups. 
3.4 | Glycemic profile 
In terms of glycemic profile, there were no significant differences in
FBS, insulin, and QUICKI between the Spirulina sauce and placebo 
groups, while HOMA-IR was significantly different between groups 
(p = .04) (Table 3). 
3.5 | Oxidative stress biomarkers 
In comparison with the baseline, MDA level decreased significantly 
in the Spirulina sauce group, while a significant increase was seen in 
TAC level. Furthermore, a significant difference was found between
the two groups for MDA and TAC (p = .04 and <.001, respectively). 
3.6 | Atherogenic index 
The atherogenic index reduced significantly in the Spirulina sauce 
group when compared to the baseline; however, no significant 
change was found in the placebo group. In comparison with the pla-
cebo group, changes in the Spirulina sauce group were significantly 
greater (p = .007). 
3.7 | Anthropometrics indexes and blood pressure 
In comparison with the baseline, weight and BMI increased in the 
placebo group and decreased in the Spirulina sauce group. However,
6  | MAZLOOMI et AL.     
        
 
      
      
      
      
      
      
      
      
 
      
      
      
      
      
      
      
      
      
      
 
      
      
 
      
      
      
      
 
      
      
      
      
TA B L E  3   Fatty liver grade, liver enzymes, cardiometabolic and oxidative stress parameters, and measures before and after the 
interventiona 
Variables Week 0 Week 8 Changes p‐valueb p‐valuec p‐valuee 
Fatty liver graded 
Placebo group 1.82 ± 0.65 1.94 ± 0.62 0.15 ± 0.68 .33 .01 .007 
Spirulina sauce group 1.78 ± 0.59 1.45 ± 0.51 −0.40 ± 0.75 .02 
ALT, U/L 
Placebo group 37.47 ± 4.37 36.26 ± 4.42 −0.57 ± 6.14 .68 .04 .03 
Spirulina sauce group 38.86 ± 4.09 33.25 ± 4.52 −5.30 ± 5.41 <.001 
AST, U/L 
Placebo group 21.78 ± 2.66 21.30 ± 3.67 −0.27 ± 3.93 .76 .02 .02 
Spirulina sauce group 23.13 ± 2.71 18.95 ± 2.72 −3.95 ± 3.70 <.001 
ALP, U/L 
Placebo group 40.52 ± 5.15 39.63 ± 4.34 −0.84 ± 6.01 .54 .50 .70 
Spirulina sauce group 43.17 ± 5.73 40.55 ± 4.24 −2.70 ± 6.64 .08 
Triglycerides, mg/dl 
Placebo group 152.83 ± 21.12 164.89 ± 38.82 12.42 ± 25.88 .05 .04 .02 
Spirulina sauce group 165.30 ± 41.20 138.65 ± 41.70 −30.35 ± 59.48 .03 
HDL cholesterol, mg/dl 
Placebo group 37.61 ± 11.27 38.58 ± 10.65 0.36 ± 9.1 .86 .03 .07 
Spirulina sauce group 42.43 ± 8.29 46.40 ± 11.64 4.45 ± 7.81 .02 
Total cholesterol, mg/dl 
Placebo group 185.96 ± 39.90 195.11 ± 24.86 5.31 ± 29.6 .42 .51 .15 
Spirulina sauce group 202.48 ± 45 186.75 ± 49.86 −13.70 ± 39.75 .14 
LDL cholesterol, mg/dl 
Placebo group 117.70 ± 40.62 123.53 ± 23.76 2.52 ± 29.46 .71 .53 .17 
Spirulina sauce group 126.96 ± 45.18 116.60 ± 41.76 −8.10 ± 22.20 .11 
Fasting blood sugar, mg/dl 
Placebo group 87.70 ± 8.63 85.68 ± 7.71 −2.57 ± 10.84 .31 .54 .55 
Spirulina sauce group 91.43 ± 7.71 87.20 ± 7.80 −3.6 ± 11.73 .18 
Insulin, μU/ml 
Placebo group 7.36 ± 2.95 8.21 ± 1.97 1.11 ± 2.43 .06 .37 .08 
Spirulina sauce group 8.30 ± 3.27 7.57 ± 2.36 −0.71 ± 2.98 .29 
HOMA-IR 
Placebo group 1.59 ± 0.66 1.75 ± 0.50 0.20 ± 0.44 .06 .49 .04 
Spirulina sauce group 1.90 ± 0.82 1.63 ± 0.56 −0.25 ± 0.66 .10 
QUICKI 
Placebo group 0.67 ± 0.10 0.63 ± 0.06 −0.04 ± 0.07 .01 .44 .10 
Spirulina sauce group 0.64 ± 0.11 0.65 ± 0.07 0.003 ± 0.10 .87 
Malondialdehyde, μmol/L 
Placebo group 3.69 ± 0.51 3.80 ± 0.28 0.18 ± 0.59 .19 .01 .04 
Spirulina sauce group 4.04 ± 0.44 3.43 ± 0.51 −0.64 ± 0.74 .001 
Total antioxidant capacity, mmol/L 
Placebo group 0.50 ± 0.35 0.43 ± 0.09 −0.08 ± 0.35 .32 <.001 <.001 
Spirulina sauce group 0.64 ± 0.26 0.79 ± 0.22 0.14 ± 0.30 .04 
(Continues) 
| 7 MAZLOOMI et AL.        
         
 
 







        
      
      
      
      
      
      
      
      
 
      
      
 
 
        
 
      





TA B L E  3   (Continued) 
Variables Week 0 Week 8 Changes p‐valueb p‐valuec p‐valuee 
Atherogenic index 
Placebo group 0.62 ± 0.14 0.63 ± 0.20 0.02 ± 0.14 .53 .01 .007 
Spirulina sauce group 0.58 ± 0.13 0.47 ± 0.18 −0.12 ± 0.18 .007 
Abbreviations: ALP, Alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; HDL, high-density lipoprotein; HOMA-IR, 
homeostasis model assessment of insulin resistance; LDL, low-density lipoprotein; QUICKI, quantitative insulin sensitivity check index. 
aData are means ± SD. 
bPaired t test was used for determination of the difference between baseline and endpoint values in each group. 
cANOVA was used for examining the significance of the difference in changes of variables between the two groups. 
dValues are the mean and SD of fatty liver grade when it was coded as 0 (no fatty liver), 1 (mild fatty liver), 2 (moderate fatty liver), and 3 (severe fatty 
liver). 
eANCOVA was used for examining the significance of the difference between the two groups with baseline values as a confounder. 
TA B L E  4   Anthropometric measures and blood pressure values during the study perioda 
Variables Week 0 Week 8 Change p‐valueb p‐valuec p‐valued 
Weight, kg 
Placebo group 72.60 ± 11.87 73.12 ± 10.34 0.33 ± 2.48 .56 .16 .05 
Spirulina sauce group 69.34 ± 10.09 68.54 ± 9.10 −0.65 ± 1.44 .06 
BMI, kg/m2 
Placebo group 24.94 ± 2.61 25.10 ± 2.52 0.16 ± 0.88 .44 .57 .10 
Spirulina sauce group 24.82 ± 2.87 24.60 ± 2.88 −0.22 ± 0.51 .07 
Waist circumference, cm 
Placebo group 95.21 ± 7.10 94.63 ± 5.02 −0.58 ± 3.48 .47 .35 .32 
Spirulina sauce group 93.78 ± 6.29 93.10 ± 5.11 −1.2 ± 4.67 .26 
SBP, mmHg 
Placebo group 127.91 ± 9.79 126 ± 7.37 −2.89 ± 7.85 .12 .68 .81 
Spirulina sauce group 130.04 ± 7.05 126.95 ± 7.12 −3.15 ± 9.18 .14 
DBP, mmHg 
Placebo group 91.65 ± 5.62 88.68 ± 5.40 −2 ± 6.06 .16 .06 .18 
Spirulina sauce group 87.60 ± 8.02 85.05 ± 6.07 −2.2 ± 7.15 .17 
aData are means ± SD. 
bPaired t test was used for determination of the difference between baseline and endpoint values in each group. 
cANOVA was used for examining the significance of the difference in changes of variables between the two groups. BMI, body mass index; SBP, 
systolic blood pressure; and DBP, diastolic blood pressure. 
dANCOVA was used for examining the significance of the difference between the two groups with baseline values as a confounder. 
none of the changes were significant within and between groups. There were no significant correlations between MDA and fatty 
Similarly, the reduction in waist circumference within and between liver grade, ALT, AST, Insulin, and HOMA-IR, where all correlation 
groups was not significant. Systolic and diastolic blood pressure re- coefficients and accompanying p-values are shown in Table 6. 
duced in both groups; however, this was nonsignificant within and 
between groups (Table 4). 
4  | DISCUSSION  
3.8 | Dietary intakes and Physical activity To the authors' knowledge, this study represents one of the first ran-
domized double-blinded clinical trial human studies to have evalu-
Energy and macronutrients' dietary intakes were not significantly ated the effect of Spirulina in NAFLD patients. Our results revealed 
different between groups during the intervention (Table 5). Similarly, that 8 weeks' consumption of Spirulina can improve fatty liver grade,
physical activity did not show significant change between two groups. oxidative stress markers, TG, and HOMA-IR index. However, no 
8  | MAZLOOMI et AL.     
 
  
     
 
    
 
    
         




    
      
      
       
    
        
        
      
      
      
      
 
      
      
      
      
      
      
      
      
      
      
      
      
   
      
      
  
 
TA B L E  5   Dietary intakes and physical activity of the participants during the interventiona 
Variables Week 0 Week 8 Change p‐valueb p‐valuec p‐valued 
Energy, kcal/day 
Placebo group 2,386.76 ± 482.59 2,374.91 ± 459.52 −19.10 ± 98.79 .41 .13 .41 
Spirulina sauce group 2,240.02 ± 407.09 21.68.51 ± 383.18 −61.32 ± 145.11 .07 
Carbohydrate, g/day 
Placebo group 328.17 ± 66.35 325.66 ± 62.61 −3.51 ± 14.25 .30 .14 .24 
Spirulina sauce group 308 ± 55.97 297.81 ± 53 −8.79 ± 18.83 .05 
Protein, g/day 
Placebo group 89.50 ± 18.09 88.69 ± 16.98 −1.08 ± 4.19 .27 .34 .10 
Spirulina sauce group 82 ± 14.75 83.77 ± 14.84 2.45 ± 5.44 .06 
Fat, g/day 
Placebo group 79.55 ± 16.08 78.64 ± 15.20 −1.16 ± 4 .22 .16 .93 
Spirulina sauce group 74.66 ± 13.56 72.34 ± 12.37 −1.97 ± 4.99 .09 
MUFA, g/day 
Placebo group 19.89 ± 3.38 19.08 ± 4.59 −1.01 ± 6.22 .48 .12 .30 
Spirulina sauce group 20 ± 4.53 21.25 ± 3.94 1.30 ± 2.87 .06 
PUFA, g/day 
Placebo group 18.68 ± 4.07 17.18 ± 3.84 −1.70 ± 4.42 .11 .10 .72 
Spirulina sauce group 16.27 ± 3.99 18 ± 4.31 1.59 ± 3.89 .08 
SFA, g/day 
Placebo group 14.87 ± 3.67 12.70 ± 4.48 −1.94 ± 5.62 .14 .33 .06 
Spirulina sauce group 13.48 ± 3.03 11.43 ± 3.55 −2.24 ± 5.73 .09 
Fiber, g/day 
Placebo group 47.08 ± 21.10 47.68 ± 18.64 1.40 ± 16.99 .72 .26 .54 
Spirulina sauce group 42.25 ± 15.35 41.37 ± 16 1.14 ± 15.49 .74 
Physical activity, Met-min/weeks 
Placebo group 685.30 ± 302.35 645.68 ± 249.27 −44.10 ± 157.66 .23 .06 .72 
Spirulina sauce group 896.17 ± 434.185 869.50 ± 439.80 −80.45 ± 284.18 .22 
Abbreviations: MUFA, monounsaturated fatty acids; PUFA, polyunsaturated fatty acids; SFA, saturated fatty acids. 
aData are means ± SD. 
bPaired t test was used for determination of the difference between baseline and endpoint values in each group. 
cANOVA was used for examining the significance of the difference in changes of variables between the two groups. 
dANCOVA was used for examining the significance of the difference between the two groups with baseline values as a confounder. 
improvement was found in FBS, insulin, QUICKI, blood pressure, and 
anthropometric indices. 
Fatty liver grade decreased significantly in the Spirulina group
in comparison with the placebo group, while a significant change in 
ALT and AST was seen between the two groups. While ALP serum 
levels were not significantly different within or between groups. To 
support the hepatoprotective effect of Spirulina, one animal study 
evaluated the capability of Spirulina maxima to inhibit fatty liver de-
velopment, which is induced in rats by a single dose of intraperito-
neal carbon tetrachloride (1 ml/kg). This study demonstrated that 
AST and liver triacylglycerides reduced, and liver cholesterol did 
not increase, after carbon tetrachloride treatment in rats fed on a 
diet with Spirulina (Torres-Durán et al., 1998). Another animal study 
also showcased inhibitory effects of Spirulina maxima on fatty liver 
exacerbation (Blé-Castillo et al., 2002). A human-based case study, 
conducted in three Mexican NAFLD patients, also showed a signifi-
cant reduction in ALT blood level concomitant to ameliorating dyslip-
idemia (Ferreira-Hermosillo et al., 2010). Indeed, further support for 
the hepatoprotective effect of Spirulina has been shown by the re-
duction of aminotransferases in NAFLD patients (Moura et al., 2011). 
The available animal data and few human studies have posited that 
the hepatoprotective effects of Spirulina are mainly attributed to 
the C-phycocyanin, β-carotene, and vitamin E content, eliciting an-
tioxidant and anti-inflammatory effects (Blé-Castillo et al., 2002; 
Browning et al., 2006; Han et al., 2006; Mazokopakis et al., 2014; 
Nagaoka et al., 2005; Neyrinck et al., 2017; Ng et al., 2007; Nseir 
et al., 2012; Premkumar et al., 2004; Serban et al., 2016; Torres-
Durán et al., 1998; Westerbacka et al., 2005). Other components 
of Spirulina, such as gamma-linolenic acid, selenium, and chloro-
phyll, have been shown to have a potential hepatoprotective roles 
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TA  B  L  E  6   Correlation analysis between 
MDA with fatty liver grade, ALT, AST, 
insulin, and HOMA-IR in patients with 
nonalcoholic fatty liver disease 
Variables 
Fatty liver grade 
Placebo group Spirulina sauce group 
MDA MDA 
Correlation





.41 .08 −.16 .49 
ALT, U/L −.32 .18 .08 .71 
AST, U/L −.18 .45 −.19 .43 
Insulin, μU/ml .30 .22 −.02 .94 
HOMA-IR .29 .23 −.04 .87 
Note: The correlation between data was examined using partial correlation by controlling MDA in 
baseline. 
p-values of <.05 were considered to indicate significance. 
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; HOMA-IR, 
homeostasis model assessment of insulin resistance; MDA, malondialdehyde 
(Torres-Durán et al., 1998). The antioxidant and anti-inflammatory 
property of Spirulina, and its constituents, might contribute to a re-
duction in inflammatory cytokines such as interleukin-6 (IL-6) and 
tumor necrosis factor-α (TNF-α) and an increase in anti-inflammatory 
cytokines such as adiponectin, indicating an improvement in oxida-
tive stress, in NAFLD patients (Blé-Castillo et al., 2002; Browning 
et al., 2006; Samuels et al., 2002). Additionally, Spirulina is report-
edly able to modulate the gut microbiota and to activate the immune 
system, a mechanism that may be involved in the improvement of 
hepatic inflammation (Moura et al., 2011). 
Although our study revealed a significant improvement in MDA,
there was no significant correlation between MDA with fatty liver 
grade and liver enzymes. Comparing the differences in both MDA 
and TAC between the groups, significant changes were evident. 
Concordant with our study, evaluating the effect of Spirulina, for 
45 days, on liver-injured mice, demonstrated a reduction of MDA 
and ALT and an increase of superoxide dismutase (SOD) activity 
(Ding et al., 2004). Moreover, these outcomes are similar to the find-
ings of Lu et al., who assessed the effects of 3-week Spirulina supple-
mentation on preventing skeletal muscle damage. Lu et al. indicated
that MDA was significantly reduced, while the activity of SOD and 
glutathione peroxidase (GP ) was significantly increased after con-x 
sumption of Spirulina supplementation (Lu et al., 2006). It has been 
shown that Spirulina can increase antioxidant enzymes such as su-
peroxide dismutase, catalase, and glutathione peroxidase (Neyrinck 
et al., 2017). The antioxidant properties of Spirulina species have re-
ceived wide attention in recent decades and have been supported 
by numerous in vitro and in vivo studies (Abdel-Daim et al., 2013; 
Upasani & Balaraman, 2003). Phycocyanin, regarded as the major 
antioxidant in Spirulina, is a free radical scavengers (hydroxyl, alkoxyl, 
and peroxyl radicals) and contributes to the downregulation of iNOS 
(inducible nitric oxide synthase) and subsequent reduction in nitrite 
production and lipid peroxidation prevention (Deng & Chow, 2010; 
Gutiérrez-Rebolledo et al., 2015; Riss et al., 2007). While in Qing 
et al., SOD and CAT (catalase) were the antioxidant enzymes report-
edly contained within Spirulina maxima (Qing et al., 2003). Other 
antioxidant enzymes found in Spirulina include total GPx, GPx-Se, 
and GR (glutathione reductase), which are posited to remain active 
and ameliorate cellular glutathione increases (Bermejo et al., 2008). 
Although, in the resent study, TG levels were improved, there
were no significant improvements in HDL-C, LDL-C, and total
cholesterol levels. Furthermore, the atherogenic index reduced
significantly in the Spirulina group when compared with the pla-
cebo group. Samuels et al. reported protective effects of 1 g/day
Spirulina on lipid profile in patients with hyperlipidemic nephrotic
syndrome (Samuels et al., 2002). Further, in Nagakoa et al., an
inhibitory effect of Spirulina platensis on jejunal cholesterol ab-
sorption was found (Nagaoka et al., 2005). According to Li-Kun H
et al., an active component of Spirulina, glycolipid H-b2, may be
responsible for triacylglyceride reduction in a dose-dependent
manner, while phycocyanin may be responsible for the hypocho-
lesterolemic effects of Spirulina via pancreatic lipase inhibition
(Han et al., 2006). Although the exact mechanism for the apparent
hypolipidemic effects of Spirulina is not fully understood (Nagaoka
et al., 2005), it has been claimed that the C-phycocyanin protein,
a main ingredient of Spirulina, has the potential to improve lipid
profile by enhancing glutathione peroxidase and superoxide dis-
mutase activity, free radical scavenging, downregulating NADPH
(nicotinamide adenine dinucleotide phosphate), oxidase expres-
sion, and lipid peroxidation. Furthermore, reductions in choles-
terol and bile acid reabsorption have been suggested (Sharma
et al., 2011; Upasani & Balaraman, 2003). Glycolipid H-b2 and phy-
cocyanin, other ingredients of Spirulina, can, reportedly, prevent
pancreatic lipase activity, while its gamma-linolenic acid (GLA), α-
linolenic acid, linolenic acid, and niacin contents have a role in the
regulation of cholesterol synthesis and hypolipidemic effects of
Spirulina (Han et al., 2006; Mazokopakis et al., 2014). Furthermore,
the activity of lipoprotein lipase and hepatic triglyceride lipase is
shown to be increased following Spirulina supplementation (Serban
et al., 2016). Another protective effect of Spirulina arises from its
specific low-calorie, low-fat, cholesterol-free, and high-protein na-
ture (Browning et al., 2006; Westerbacka et al., 2005), which might
10  | MAZLOOMI et AL.     
 
  
    





     
     
 
 
   
        
   
 
         
   
   
 
   
 
    
  
         
   
 
     
         
 
        
  
          
 
     
 
          
 
        






     
   
 
        
 
         
 
   
 
  
       
 
 
    
contribute to weight loss and thus support a reduction in TG levels
and decelerate the HDL apoA-I catabolism, with a simultaneous
decline in the secretion of HDL apoA-I (Han et al., 2006; Nagaoka
et al., 2005; Ng et al., 2007; Nseir et al., 2012). 
In terms of glycemic profile, HOMA-IR decreased significantly, 
and while FBS and insulin decreased, these changes were not sta-
tistically significant. In Parikh et al., 2 g/day Spirulina supplementa-
tion for 8 weeks revealed a statistically significant effect of Spirulina
on reducing fasting blood glucose and postprandial blood glucose 
levels as well as HbA1c level (Parikh et al., 2001). Some other stud-
ies have also shown that Spirulina consumption could reduce blood
glucose levels (Aissaoui et al., 2017; Huang et al., 2018). Spirulina
can putatively reduce blood glucose levels by stimulating β cell ac-
tivity and increasing glucose transport to peripheral tissues (Layam 
& Reddy, 2006); moreover, it has been posited that the hypoglycemic 
effect of Spirulina might arise from its fiber content, creating less 
glucose absorption, and the high-quality protein in Spirulina, which
can generate peptides and polypeptides and trigger insulin secre-
tion (Hernández-Alonso et al., 2017), thus maintaining the plasma 
glucose level. 
In our study, there was no significant improvement in anthro-
pometric indices. Indeed, there are limited studies regarding the ef-
fects of Spirulina on weight loss (Mazokopakis et al., 2014). However,
discordant with our results, another study found spirulina could elicit
positive effects on body weight, which might be owing to the rela-
tively higher dose and a longer period of intervention (6 g/day for 
6 months in comparison with 1 g/day for 3 months in our study). The 
potential effect of Spirulina on weight loss might be attributable to 
its low-fat and low-carbohydrate content (Mazokopakis et al., 2014). 
Additionally, Spirulina is a source of phenylalanine, a potent releaser
of cholecystokinin, which might help to regulate the brain's appe-
tite center (Ballinger & Clark, 1994; Gibbs et al., 1976; Silverstone & 
Goodall, 1984). 
Although the effect of Spirulina maxima in the inhibition of syn-
thesis and releasing of arachidonic acid, and its vasoconstricting
metabolites, and increasing nitric oxide synthesis (a well-known 
vasodilatation metabolite) is shown in some studies (Mascher
et al., 2006), another potential mechanism to ameliorate blood pres-
sure increases might be attributed to the inhibition of platelet aggre-
gation, anti-inflammatory effects, and the high potassium and low 
sodium contents of Spirulina (Guan et al., 2007; Hsiao et al., 2005). 
In our study, we did not find any significant ameliorating effects of 
Spirulina on blood pressure; however, this might be due to the nor-
mal baseline blood pressure levels and weight of our participants. 
4.1 | Strengths and limitations 
This study represents one of the first randomized double-blinded
clinical trial human studies to have evaluated the effect of Spirulina
in NAFLD patients. In addition, potential errors in grading fatty liver 
were decreased due to the radiologist being blinded to the group al-
location of the patients. However, despite the strength and novelty 
of our study, several limitations must be considered. For instance, 
a relatively short period of intervention and a low sample size con-
ceivably hindered the identification of effects of Spirulina in some 
parameters; while a lack of measurement of inflammatory factors 
could have further impacted the overall results. Therefore, in light 
of the aforementioned strengths and limitations, further studies
with longer intervention duration, larger sample size, and additional
evaluation of inflammatory factors are suggested. 
5  | CONCLUSION  
We found that 8 weeks' supplementation of Spirulina improved fatty
liver grade, oxidative stress markers, TG, and HOMA-IR; however, no 
significant change was found in blood pressure and anthropometric 
indices. 
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